BlossomHill prices upsized IPO at $150M, debuts on Nasdaq
What's the deal? BlossomHill Therapeutics, a San Diego clinical-stage cancer drug developer, priced an upsized initial public offering of 9,375,000 shares at $16.00 each, raising $150 million in gross proceeds. Shares were set to begin trading on the Nasdaq Global Select Market on August 7, 2026, under the ticker "BLSM."
Why now? The offering was upsized, and underwriters hold a 30-day option to buy up to 1,406,250 additional shares at the public price — signals of solid investor demand. The offering is expected to close on August 10, 2026.
What's the endgame? BlossomHill applies a chemistry-based approach to design small molecule medicines for hard-to-treat cancers. It was founded and led by J. Jean CuiDealroom has a profile for this one. Try Dealroom →, whose track record includes three FDA-approved drugs.
Who's backing it? J.P. Morgan, Leerink PartnersDealroom has a profile for this one. Try Dealroom →, and Guggenheim SecuritiesDealroom has a profile for this one. Try Dealroom → are lead book-running managers. LifeSci CapitalDealroom has a profile for this one. Try Dealroom → and H.C. WainwrightDealroom has a profile for this one. Try Dealroom → & Co. are joint book-running managers.
The signal: An upsized biotech listing shows public-market appetite for oncology names with experienced founders, even at the clinical stage. Whether BlossomHill holds after debut will test how far that demand extends.
Read more: GlobeNewswire
Image credit: Generated with Gemini
